Researchers at the University of Florida unveiled a DNA-guided CRISPR-Cas12 approach designed to target cellular RNA using a DNA-based guide scaffold instead of guide RNA. The work, published in Nature Biotechnology, is presented as a way to retool Cas12 nucleases for programmable RNA modulation. The ΨDNA system mimics the crRNA scaffold in a reverse orientation to enable binding to RNA and trigger trans-cleavage. The team reported 100% accurate hepatitis C virus RNA detection in clinical samples and 70–95% knockdown of endogenous RNA transcripts in human cell lines. A core rationale is that RNA-guided systems can face instability and off-target concerns, while DNA guides could improve robustness and reduce guide-related constraints. The publication adds to a growing set of genome-engineering innovations aimed at precision control of transcriptomes while potentially improving diagnostic and therapeutic delivery characteristics.